Cibus Reports Q1 Gene Editing Progress Amid Financial Loss

Cibus, Inc. reported mixed Q1 2025 results, highlighting significant regulatory milestones and commercial validation for its gene editing technology, particularly in rice, canola, and soybean crops. The company achieved positive regulatory decisions in multiple regions and advanced its sustainable ingredient programs, though it also faced financial challenges including a $49.4 million net loss driven by goodwill impairment and increased expenses. With cash reserves sufficient to fund operations into Q3 2025, Cibus plans to expand its trait development pipeline and commercial partnerships. Meanwhile, Cineplex experienced a 10.3% decline in total revenues and a net loss of $36.6 million in Q1 2025 but showed growth in cinema media and digital advertising revenues, buoyed by a strong film slate and post-strike industry optimism. Cineplex's CEO emphasized robust audience engagement and a positive outlook for shareholder value despite recent financial instability. Both companies demonstrate operational progress amid financial headwinds, reflecting mixed but cautiously optimistic outlooks for their respective industries.